Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2015

View Archived Issues

Novel molecular markers of prostate cancer

Cerdelga approved for Gaucher's disease in Japan

RORgamma inverse agonists with good drug-like properties

Ono describes novel peptidic FXIa inhibitors

IMO-8400 as a potential therapy for psoriasis and other immune-mediated inflammatory diseases

Naldemedine meets primary endpoint in phase III study in opioid-induced constipation

New trial evaluates farletuzumab in patients with platinum-sensitive ovarian cancer and low CA125

FDA accepts Neurotech's IND for phase II study of NT-503 encapsulated cell therapy for wet AMD

EMA committee recommends approval of Akynzeo

Aurigene discloses PD-1 signalling inhibitors

FDA grants priority review for carfilzomib sNDA

CF-101 phase II/III psoriasis trial fails to achieve primary endpoint

ILDONG presents novel PARP inhibitors

STG-320 immunotherapy tablet approved in Japan for house dust mite-induced allergic rhinitis

Lu-177-DOTA-girentuximab tested in patients with advanced renal cell carcinoma

Movantik launched in the U.S.

Paion announces beginning of U.S. phase III trial of remimazolam

CP-2: a tricyclic pyrone compound in Alzheimer's disease

The Medicines Company receives European approval for three hospital acute care products

Horizon Pharma to acquire Hyperion Therapeutics

Avedro receives complete response letter from FDA on corneal cross-linking system NDA

Unither Virology reports new deoxynojirimycin derivates

Chromocell patents sodium channel modulators

Dyax reports phase Ib results and fast track designation for DX-2930 in HAE

Selvita initiates IND-enabling studies for SEL-24

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...